Patents by Inventor Richard Rampulla

Richard Rampulla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic CETP inhibitors
    Patent number: 8642576
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: February 4, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • HETEROCYCLIC CETP INHIBITORS
    Publication number: 20120322761
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Application
    Filed: August 29, 2012
    Publication date: December 20, 2012
    Inventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • Heterocyclic CETP inhibitors
    Patent number: 8304403
    Abstract: Compounds of formula Ia and Ib and wherein A, B, C and R1 are described herein.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: November 6, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • Hepatitis C Virus Inhibitors
    Publication number: 20120195857
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 2, 2012
    Inventors: Makonen Belema, Pothukanuri Srinivasu, John A. Bender, Omar D. Lopez, Qi Chen, Richard A. Rampulla, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell
  • HETEROCYCLIC CETP INHIBITORS
    Publication number: 20100267669
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Application
    Filed: June 10, 2010
    Publication date: October 21, 2010
    Inventors: Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • Heterocyclic CETP inhibitors
    Patent number: 7790770
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: September 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, Heather Finlay, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7655689
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: February 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7517904
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: April 14, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • HETEROCYCLIC CETP INHIBITORS
    Publication number: 20070135631
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Application
    Filed: November 13, 2006
    Publication date: June 14, 2007
    Inventors: Mark Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi Harikrishnan, Ji Jiang, James Johnson, Muthoni Kamau, R. Lawrence, Jianqing Li, John Lloyd, Michael Miller, Zulan Pi, Jennifer Qiao, Richard Rampulla, Jacques Roberge, Tammy Wang, Yufeng Wang, Wu Yang
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7141578
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20060264459
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 15, 2006
    Publication date: November 23, 2006
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20060223832
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 12, 2004
    Publication date: October 5, 2006
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20050272799
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: July 7, 2005
    Publication date: December 8, 2005
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20050192253
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 25, 2004
    Publication date: September 1, 2005
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20040077605
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: December 18, 2002
    Publication date: April 22, 2004
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Ring-fused thienopyrimidinedione derivatives
    Patent number: 4939137
    Abstract: The synthesis of ring-fused thienopyrimidinedione derivatives is described. The novel ring-fused thienopyrimidinedione derivatives are generally vasodilating agents and antihypertensive agents and as such are useful as cardiovascular agents.
    Type: Grant
    Filed: June 28, 1989
    Date of Patent: July 3, 1990
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Ronald K. Russell, Richard A. Rampulla